Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 17/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3810866 | 0.90 | XPO1 (0.55) | XPO1 | |
| SCHEMBL4997706 | 0.88 | XPO1 (0.53) | XPO1EPHX2PPARG | |
| SCHEMBL5001580 | 0.87 | XPO1 (0.53) | XPO1 | |
| SCHEMBL8141359 | 0.85 | XPO1 (0.58) | XPO1 | |
| SCHEMBL1592570 | 0.85 | XPO1 (0.52) | XPO1 | |
| SCHEMBL5001387 | 0.84 | XPO1 (0.49) | XPO1 | |
| SCHEMBL1592931 | 0.84 | XPO1 (0.57) | XPO1 | |
| SCHEMBL1592511 | 0.83 | XPO1 (0.65) | XPO1 | |
| SCHEMBL1592464 | 0.82 | XPO1 (0.61) | XPO1 | |
| SCHEMBL1592393 | 0.82 | XPO1 (0.53) | XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275057-A1 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275057-A1 | Compounds with anti-cancer activity | CDKN1A, CDC25C, DDB1 | XPO1 280/4885EPHX2 1980/4885PPARG 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.